Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18986523 | 0.84 | KDM4E (0.48) | NAAAGRIN2BAOC3SLC18A3OPRM1 | |
| SCHEMBL8260718 | 0.82 | HRH3 (0.49) | CYP2D6HRH3KCNH2AGTR2GRIN2B | |
| SCHEMBL26618008 | 0.77 | OPRM1 (0.47) | HRH3AGTR2NAAAGRIN2BSLC18A3 | |
| SCHEMBL18986789 | 0.77 | TSHR (0.45) | CYP2D6NAAAGRIN2BAOC3SLC18A3 | |
| SCHEMBL25792208 | 0.76 | HRH3 (0.33) | CYP2D6HRH3 | |
| SCHEMBL8258573 | 0.75 | KMT2A (0.49) | HRH3AGTR2NAAAGRIN2BSLC18A3 | |
| SCHEMBL25789796 | 0.73 | CYP2D6 (0.35) | CYP2D6HRH3 | |
| SCHEMBL30942895 | 0.73 | C5AR1 (0.41) | HRH3NAAAGRIN2BAOC3SLC18A3 | |
| SCHEMBL18986537 | 0.73 | JAK2 (0.62) | TACR1 | |
| SCHEMBL14507968 | 0.72 | OPRM1 (0.54) | CYP2D6HRH3KCNH2TACR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127354-A1 | 2,4,6,7-TETRASUBSTITUTED QUINOLINE COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127354-A1 | 2,4,6,7-TETRASUBSTITUTED QUINOLINE COMPOUNDS AS INHIBITORS OF DNA METHYLTRANSFERASES | DNMT3B, DNMT1, DNMT3A | CYP2D6 175/4885HRH3 2406/4885KCNH2 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.